Annovis Bio(ANVS) - 2025 Q3 - Quarterly Results

Exhibit 99 ● Annovis' pivotal Phase 3 study in early AD (NCT06709014) remains on track, with all 84 clinical sites fully activated, recruiting, and treating participants across the U.S. ● The trial has generated robust participation, reflecting growing enthusiasm from the patient community. The screen failure rate remains within expected projections. ● The first patients have successfully completed the 6-month treatment period, a key milestone for the upcoming symptomatic readout, reinforcing steady progres ...